Pre-Transplant Radiation for Lung Cancer

(NORTh STAR Trial)

Recruiting in Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: Marc de Perrot

Disqualifiers: Mediastinal nodes metastasis, distant metastasis, others

No Placebo Group

Approved in 6 Jurisdictions

Trial Summary

What is the purpose of this trial?

This trial involves giving short bursts of radiation to lung cancer tumors before a lung transplant. It targets patients with lung cancer who are getting a lung transplant. The radiation might help the body’s immune system recognize and fight the cancer, reducing the chance of it coming back after the transplant.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of pre-transplant radiation treatment for lung cancer?

Research shows that preoperative radiation treatment can improve survival rates in lung cancer patients. In one study, patients who received radiation before surgery had a 5-year survival rate of 58% compared to 43% for those who only had surgery. ^{1 2 3 4 5}

Is pre-transplant radiation therapy generally safe for humans?

Research shows that radiation therapy, including thoracic radiation, has been studied for safety in lung cancer patients. Some studies report on the safety of combining radiation with other treatments, noting potential side effects like pneumonitis (lung inflammation). Overall, while radiation therapy is generally considered safe, it can have side effects, and careful monitoring is recommended. ^{6 7 8 9 10}

How does pre-transplant radiation treatment for lung cancer differ from other treatments?

Pre-transplant radiation treatment for lung cancer is unique because it is administered before surgery to shrink the tumor and improve the chances of complete surgical removal, potentially preventing the spread of cancer. This approach can lead to better survival rates compared to surgery alone, as it directly targets cancer cells and surrounding tissues, making it a beneficial addition to the treatment plan. ^{5 11 12 13 14}

Research Team

Eligibility Criteria

This trial is for adults over 18 with end-stage lung disease and suspected early-stage lung cancer, who are eligible for a lung transplant but can't have curative surgery. It's not for those with previous chest radiation, mediastinal node or distant metastasis, or other conditions that could affect participation.

Inclusion Criteria

Subjects must be able to understand the potential risks and benefits of the study and must be able to read and provide written, informed consent for the study.

My lung cancer is in early stage but can't be treated with surgery or targeted radiation.

I had surgery to remove a lung tumor and have no other cancer spread that can be treated.

Exclusion Criteria

You have a medical condition that may affect your ability to follow the treatment as required, according to the team's evaluation.

I am under 18 years old.

My cancer has spread to the lymph nodes in my chest, confirmed by a specific biopsy.

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Radiation

Non-ablative oligofractionated radiation therapy (NORT) is administered to determine the maximum tolerated dose (MTD) before lung transplantation.

3-6 weeks

Multiple visits for radiation sessions

Surgical Transplantation

Resection of the radiated tumor at the time of lung transplantation.

1 week

Follow-up

Participants are monitored for safety and effectiveness after treatment, including assessment of maximum tolerated dose and patient morbidity.

Up to four years

Treatment Details

Interventions

• Radiation (Radiation Therapy)

Trial Overview The study tests non-ablative oligofractionated radiation therapy (NORT) before lung transplantation to see if it's safe and can act as a 'radiovaccination', potentially reducing cancer recurrence by triggering an immune response against the tumor.

Participant Groups

Group I: Experimental: Radiation Experimental Treatment 1 Intervention

Patients will be differentiated into 4 groups: 1. Patients with end-stage interstitial lung disease (ILD) and suspected stage I (up to 4 cm) primary lung cancer 2. Patients with end-stage lung disease other than ILD (e.g. emphysema/COPD, cystic fibrosis and pulmonary hypertension) and suspected stage I (up to 4 cm) primary lung cancer 3. Patients with multifocal primary lung cancer (e.g. multifocal adenocarcinoma) in the absence of nodal metastasis and distant metastasis. 4. Patients with isolated pulmonary metastasis in the absence of other sites of malignancy (primary and metastatic). For this study, different doses will be used for each different group depending on their tumour size. The first 3 patients will start with a dose of 4 Gy, for the ILD group, or 8 Gy, for the non ILD group. The doses are then increased incrementally until the dose limiting toxicity is reached.

Radiation is already approved in Canada, Japan, China, Switzerland for the following indications:

Approved in Canada as Radiation Therapy for:

• Cancer treatment
• HPV-positive throat cancer
• Various types of tumors

Approved in Japan as Radiation Therapy for:

• Cancer treatment
• HPV-positive throat cancer
• Various types of tumors

Approved in China as Radiation Therapy for:

• Cancer treatment
• HPV-positive throat cancer
• Various types of tumors

Approved in Switzerland as Radiation Therapy for:

• Cancer treatment
• HPV-positive throat cancer
• Various types of tumors

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

Toronto General Hospital, University Health Network Toronto, Canada

Who Is Running the Clinical Trial?

Marc de Perrot

Lead Sponsor

Trials

2

Recruited

40+

University Health Network, Toronto

Lead Sponsor

Trials

1555

Recruited

526,000+

Dr. Kevin Smith

University Health Network, Toronto

Chief Executive Officer since 2018

Professor at McMaster University and University of Toronto

Dr. Brad Wouters

University Health Network, Toronto

Chief Medical Officer since 2020

MD from University of Toronto

Findings from Research

Radiation therapy is a common treatment for locally advanced non-small cell lung cancer, but only 5% of patients survive for 5 years, highlighting the need for improved treatment strategies.

Advancements in radiobiology and technology, such as 3D planning using CT and MRI, have enhanced local control and survival, and combining radiation with chemotherapy may offer further benefits, although the optimal sequence of these treatments remains unclear.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Curative radiotherapy in locally advanced non-small-cell bronchial carcinoma (NSCLC)]. von Briel, C., Betticher, DC., Ris, HB.[2008]

In a study of 96 lung cancer patients who received thoracic radiotherapy (TRT) after PD-(L)1 inhibitor treatment, nearly 49% developed symptomatic treatment-related pneumonitis, indicating a significant safety concern with this treatment sequence.

Independent risk factors for developing pneumonitis included pulmonary emphysema and lung V20 exposure, highlighting the need for careful patient selection and monitoring when using TRT after PD-(L)1 inhibitors.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Safety of thoracic radiotherapy after PD-(L)1 inhibitor treatment in patients with lung cancer. Chen, Y., Liu, X., Huang, Z., et al.[2022]

In a study of 60 patients receiving combined immunotherapy and thoracic radiation therapy (iRT), no patients experienced severe grade ≥4 toxicities, indicating a favorable safety profile for this treatment approach.

While some patients did experience grade 3 toxicities, particularly pulmonary and hematologic issues, the overall short-term safety of iRT suggests it can be administered without significant risk of severe adverse effects.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Safety of Combined Immunotherapy and Thoracic Radiation Therapy: Analysis of 3 Single-Institutional Phase I/II Trials. Verma, V., Cushman, TR., Selek, U., et al.[2022]

The combination of PD-1/PD-L1 blockade with thoracic radiotherapy is now the standard treatment for locally advanced non-small-cell lung cancer, but safety data is primarily from retrospective studies and small clinical trials.

There is a need for longer and more rigorous follow-up studies to better understand the pulmonary safety and potential toxicity of this combined therapy in patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Rethinking pulmonary toxicity in advanced non-small cell lung cancer in the era of combining anti-PD-1/PD-L1 therapy with thoracic radiotherapy. Li, M., Gan, L., Song, A., et al.[2019]

Radiation therapy (RT) is a key treatment for lung cancer, aiming to effectively target tumors while minimizing side effects, influenced by factors like tumor type and location.

Recent advancements in RT techniques, such as intensity-modulated radiation therapy and stereotactic body radiation therapy, have improved treatment efficacy and significantly reduced toxicity for patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The Radiotherapy: Basic Concepts And Recent Techniques Advances For Thoracic Malignancies. Amorim, M., Costa, PS., Costa, MA.[2023]

References

1. Switzerland pubmed.ncbi.nlm.nih.gov

[Curative radiotherapy in locally advanced non-small-cell bronchial carcinoma (NSCLC)]. [2008]

2. United States pubmed.ncbi.nlm.nih.gov

Lung cancer. [2019]

3. Russia (Federation) pubmed.ncbi.nlm.nih.gov

[Surgical treatment of lung cancer in patients with preoperative radiation therapy]. [2006]

4. United States pubmed.ncbi.nlm.nih.gov

The role of radiotherapy in non-small cell lung cancer. [2019]

5. United States pubmed.ncbi.nlm.nih.gov

Evaluation of short-course preoperative irradiation in the treatment of resectable bronchus carcinoma: long-term analysis of a randomized pilot-study. [2019]

6. United States pubmed.ncbi.nlm.nih.gov

Safety of thoracic radiotherapy after PD-(L)1 inhibitor treatment in patients with lung cancer. [2022]

7. United States pubmed.ncbi.nlm.nih.gov

Association Between Physician- and Patient-Reported Symptoms in Patients Treated With Definitive Radiation Therapy for Locally Advanced Lung Cancer in a Statewide Consortium. [2022]

8. United States pubmed.ncbi.nlm.nih.gov

Safety of Combined Immunotherapy and Thoracic Radiation Therapy: Analysis of 3 Single-Institutional Phase I/II Trials. [2022]

9. Netherlands pubmed.ncbi.nlm.nih.gov

Rethinking pulmonary toxicity in advanced non-small cell lung cancer in the era of combining anti-PD-1/PD-L1 therapy with thoracic radiotherapy. [2019]

10. United States pubmed.ncbi.nlm.nih.gov

Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibition. [2022]

11. Portugal pubmed.ncbi.nlm.nih.gov

The Radiotherapy: Basic Concepts And Recent Techniques Advances For Thoracic Malignancies. [2023]

12. Switzerland pubmed.ncbi.nlm.nih.gov

[Radiotherapy in malignant lung tumors]. [2008]

13. Australia pubmed.ncbi.nlm.nih.gov

Preoperative irradiation for carcinoma of the bronchus. [2019]

14. China pubmed.ncbi.nlm.nih.gov

[Preoperative radiotherapy and ultrastructural pathology of lung cancer]. [2006]